Parallax Volatility Advisers’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Parallax Volatility Advisers’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-26,800	Closed	-$1.48M	–	2877
2021 Q4	$1.48M	Sell	26,800 -191,124	-88%	-$9.97M	﹤0.01%	1155
2021 Q3	$11.5M	Buy	+217,924	New	+$12.9M	0.01%	602
2021 Q1	–	Sell	-46,467	Closed	-$4.6M	–	1424
2020 Q4	$4.6M	Buy	+46,467	New	+$5.68M	﹤0.01%	975
2018 Q3	–	Sell	-25	Closed	-$2.64K	–	2943
2018 Q2	$2K	Buy	+25	New	+$2.42K	﹤0.01%	1929

Other funds holding LKFT

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

SBH

Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return

Parallax Volatility Advisers's LKFT Position: Q1 2022 in Review

Parallax Volatility Advisers sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q1 2022, closing a stake of 26,800 shares — an estimated $1.48M sold.

Parallax Volatility Advisers first reported a position in LKFT in Q2 2018 and held it in 4 quarters. The position peaked at $11.5M in Q3 2021. 90 funds tracked by Wall St. Rank hold LKFT as of Q1 2022.

Parallax Volatility Advisers reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q1 2022 after selling out during the quarter.
Parallax Volatility Advisers sold 26,800 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2022, an estimated $1.48M.
Parallax Volatility Advisers first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2018 and held it in 4 quarters.
Parallax Volatility Advisers's Lakefront Biotherapeutics American Depositary Shares position peaked at $11.5M in Q3 2021.
90 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2022.

Based on Parallax Volatility Advisers's 13F filing for Q1 2022, filed 16 May 2022.